Subscribe

Spotlight -

Richard Furie, MD

Articles by Richard Furie, MD

Belimumab With MMF Attenuates eGFR Decline in Lupus Nephritis

Belimumab With MMF Attenuates eGFR Decline in Lupus Nephritis

ByRichard Furie, MD

June 5th 2026

Richard Furie, MD, discusses a post hoc analysis of BLISS-LN showing a markedly slower rate of kidney function loss with belimumab versus PBO.

Achieving Complete Renal Response and Reducing Corticosteroid Use in Lupus Nephritis Treatment With Obinutuzmab, with Richard Furie, MD

Achieving Complete Renal Response and Reducing Corticosteroid Use in Lupus Nephritis Treatment With Obinutuzmab, with Richard Furie, MD

ByVictoria Johnson,Richard Furie, MD

February 21st 2025

Furie discussed topline data from the REGENCY trial and key secondary endpoints.

Identifying B-cell Depleting Agents for Lupus Nephritis, with Richard Furie, MD

Identifying B-cell Depleting Agents for Lupus Nephritis, with Richard Furie, MD

ByVictoria Johnson,Richard Furie, MD

February 14th 2025

Furie discussed his experiences in evaluating therapies such as rituximab and now obinutuzumab for lupus nephritis.

Latest Updated Articles

Achieving Complete Renal Response and Reducing Corticosteroid Use in Lupus Nephritis Treatment With Obinutuzmab, with Richard Furie, MD
February 21st 2025
Identifying B-cell Depleting Agents for Lupus Nephritis, with Richard Furie, MD
February 14th 2025

Trending on Rheumatology Live

Slow But Steady: Real-World Data Supports Avacopan Use in GPA/MPA

EULAR 2026: Expert Interviews and Late Breakers to Watch

Belimumab With MMF Attenuates eGFR Decline in Lupus Nephritis

Izokibep Sustains PsA Efficacy at 52 Weeks, With Philip Mease, MD

Prior Relapse Predicts Faster Flare After Stopping Upadacitinib in GCA